MIMEDX Q3 Net Income Doubles on Strong Sales Growth

TL;DR

**MDXG is crushing it with sales and profit growth, making it a strong buy in the medical device space.**

AI Summary

MIMEDX GROUP, INC. (MDXG) reported a significant increase in net sales and net income for the three and nine months ended September 30, 2025. Net sales for the three months ended September 30, 2025, surged to $113.7 million, up from $84.1 million in the prior year, representing a 35.2% increase. Net income for the same period more than doubled to $16.7 million, compared to $8.1 million in 2024. For the nine months ended September 30, 2025, net sales reached $300.5 million, a 17.4% increase from $256.0 million in 2024, while net income was $33.4 million, a slight decrease from $35.0 million in 2024, primarily due to higher operating expenses. The company's cash and cash equivalents increased to $142.1 million as of September 30, 2025, from $104.4 million at December 31, 2024. Key business changes include a substantial increase in accounts receivable, net, to $78.2 million from $55.8 million, and a rise in inventory to $26.5 million from $23.8 million. Strategic outlook includes continued focus on wound care, burn, and surgical sectors, with an emerging international presence, particularly in Japan. Risks include the need to comply with FDA regulations and potential impacts from pending litigation.

Why It Matters

This strong performance, particularly the 35.2% increase in Q3 net sales and the doubling of net income, signals robust demand for MDXG's wound care and surgical products, which is crucial for investor confidence. The significant increase in cash and cash equivalents to $142.1 million provides the company with greater financial flexibility for future investments and acquisitions, potentially strengthening its competitive position against rivals in the medical device sector. For employees, this growth could mean job security and expansion opportunities, while customers benefit from continued innovation in healing solutions. The broader market may see this as an indicator of health in the specialized medical device segment, especially for companies focused on FDA-regulated products.

Risk Assessment

Risk Level: medium — The company's accounts receivable, net, increased significantly to $78.2 million as of September 30, 2025, from $55.8 million at December 31, 2024, and credit loss expense for the nine months ended September 30, 2025, was $3.1 million, up from $0.1 million in 2024. This substantial increase in receivables and credit loss expense indicates potential collection risks and could impact future cash flow if not managed effectively.

Analyst Insight

Investors should consider MDXG's strong revenue and net income growth as a positive indicator, but closely monitor the rising accounts receivable and credit loss expense. A deeper dive into the aging of receivables and the company's collection strategies would be prudent to assess the sustainability of its cash flow generation.

Financial Highlights

debt To Equity

0.07

revenue

$113.7M

operating Margin

19.5%

total Assets

$319.0M

total Debt

$18.2M

net Income

$16.7M

eps

$0.11

gross Margin

83.5%

cash Position

$142.1M

revenue Growth

+35.2%

Revenue Breakdown

Key Numbers

• $113.7M — Net Sales (Q3 2025) (Increased 35.2% from $84.1M in Q3 2024)
• $16.7M — Net Income (Q3 2025) (More than doubled from $8.1M in Q3 2024)
• $300.5M — Net Sales (YTD 2025) (Increased 17.4% from $256.0M in YTD 2024)
• $142.1M — Cash and Cash Equivalents (Increased from $104.4M at Dec 31, 2024)
• $78.2M — Accounts Receivable, Net (Increased from $55.8M at Dec 31, 2024, indicating potential collection risk)
• $3.1M — Credit Loss Expense (YTD 2025) (Significantly increased from $0.1M in YTD 2024)
• 148,102,159 — Common Shares Outstanding (As of October 20, 2025)
• $238.9M — Total Stockholders' Equity (Increased from $193.1M at Dec 31, 2024)
• $49.0M — Net Cash Flows from Operating Activities (YTD 2025) (Slightly increased from $47.4M in YTD 2024)
• $57.9M — Accumulated Deficit (Reduced from $91.3M at Dec 31, 2024, indicating improved profitability)

Key Players & Entities

• MIMEDX GROUP, INC. (company) — registrant
• United States Food and Drug Administration (regulator) — regulates company products
• SEC (regulator) — Securities and Exchange Commission
• Citizens Credit Agreement (company) — debt facility provider
• $113.7 million (dollar_amount) — net sales for three months ended September 30, 2025
• $16.7 million (dollar_amount) — net income for three months ended September 30, 2025
• $300.5 million (dollar_amount) — net sales for nine months ended September 30, 2025
• $142.1 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $78.2 million (dollar_amount) — accounts receivable, net, as of September 30, 2025
• $3.1 million (dollar_amount) — credit loss expense for nine months ended September 30, 2025

FAQ

Risk Factors

• FDA Regulatory Compliance [high — regulatory]: The company's products are subject to stringent FDA regulations. Non-compliance could lead to product recalls, manufacturing disruptions, and significant penalties, impacting sales and reputation.
• Pending Litigation [medium — legal]: The company is involved in pending litigation, the outcomes of which are uncertain. Adverse judgments could result in substantial financial liabilities and negatively affect financial condition.
• Accounts Receivable Growth [medium — financial]: Accounts receivable increased to $78.2 million from $55.8 million. While indicative of sales growth, a significant increase in this balance, coupled with a rise in credit loss expense to $3.1 million from $0.1 million, warrants close monitoring for potential collection issues.
• Inventory Management [low — operational]: Inventory levels rose to $26.5 million from $23.8 million. While necessary to support sales growth, an inefficient inventory management could lead to increased holding costs or obsolescence.

Industry Context

MIMEDX GROUP operates in the regenerative medicine and biologics sector, focusing on advanced wound care, burn treatment, and surgical applications. The industry is characterized by significant R&D investment, stringent regulatory oversight (FDA), and a competitive landscape with both established players and emerging biotech firms. Growth is driven by an aging population, increasing prevalence of chronic diseases, and advancements in regenerative therapies.

Regulatory Implications

The company's reliance on FDA-approved products places it under continuous regulatory scrutiny. Any adverse findings, delays in approvals, or changes in regulatory pathways could significantly impact product availability, market access, and financial performance. Compliance with evolving FDA guidelines is paramount for sustained operations and growth.

What Investors Should Do

1. Monitor Accounts Receivable and Credit Loss Expense
2. Evaluate SG&A Expense Control
3. Assess International Expansion Strategy

Key Dates

• 2025-09-30: End of Q3 2025 — Reported strong net sales of $113.7M and net income of $16.7M, indicating robust operational performance.
• 2025-09-30: End of Nine Months 2025 — Achieved YTD net sales of $300.5M, a 17.4% increase, demonstrating sustained growth momentum.
• 2025-09-30: Balance Sheet Date — Cash and cash equivalents stood at $142.1M, a healthy increase, supporting future investments and operational needs.
• 2024-12-31: End of Fiscal Year 2024 — Provided a baseline for comparison, with cash and cash equivalents at $104.4M and total assets at $263.9M.

Glossary

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income. A reduction indicates improved profitability over time. (MDXG's accumulated deficit reduced from $(91.3M) to $(57.9M), signaling a positive trend towards overall profitability.)

Accounts Receivable, Net

The total amount of money owed to a company by its customers for goods or services delivered, net of any allowance for doubtful accounts. (The increase to $78.2M from $55.8M suggests higher sales volume but also raises concerns about collection efficiency and potential credit risk.)

Credit Loss Expense

The expense recognized by a company for estimated uncollectible accounts receivable. (The significant jump from $0.1M to $3.1M for the nine months ended September 30, 2025, directly correlates with the increase in accounts receivable and highlights a growing concern about customer payment.)

Gross Profit Margin

Gross profit divided by net sales, expressed as a percentage. It indicates how efficiently a company is managing its cost of goods sold. (MDXG's gross margin remained strong at 83.5% for Q3 2025, indicating effective cost management relative to sales.)

Operating Margin

Operating income divided by net sales, expressed as a percentage. It measures a company's profitability from its core business operations. (MDXG's operating margin for Q3 2025 was 19.5%, showing healthy profitability from its primary activities.)

Year-Over-Year Comparison

Compared to the prior year, MIMEDX GROUP, INC. (MDXG) has demonstrated robust top-line growth, with Q3 net sales increasing by 35.2% to $113.7M and YTD sales up 17.4% to $300.5M. Net income for Q3 more than doubled, reflecting improved short-term profitability. However, YTD net income saw a slight decrease due to higher operating expenses, particularly SG&A. The balance sheet shows a strengthened cash position ($142.1M vs $104.4M) but also a notable increase in accounts receivable and a significant rise in credit loss expense, indicating potential collection challenges.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share MDXG The Nasdaq Stock Market

Filing Documents

• mdxg-20250930.htm (10-Q) — 855KB
• ex311ceosox21.htm (EX-31.1) — 10KB
• ex312cfosox2.htm (EX-31.2) — 10KB
• ex321ceosox1.htm (EX-32.1) — 5KB
• ex322cfosox1.htm (EX-32.2) — 5KB
• 0001376339-25-000103.txt ( ) — 4966KB
• mdxg-20250930.xsd (EX-101.SCH) — 32KB
• mdxg-20250930_cal.xml (EX-101.CAL) — 82KB
• mdxg-20250930_def.xml (EX-101.DEF) — 96KB
• mdxg-20250930_lab.xml (EX-101.LAB) — 460KB
• mdxg-20250930_pre.xml (EX-101.PRE) — 310KB
• mdxg-20250930_htm.xml (XML) — 651KB

FINANCIAL INFORMATION

Part I FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1 Financial Statements (Unaudited) Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Stockholders' Equity 7 Condensed Consolidated Statements of Cash Flows 9 Notes to the Condensed Consolidated Financial Statements 10

Management's Discussion and Analysis of Financial Condition and Results of Operations 18

Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations 18

Quantitative and Qualitative Disclosures About Market Risk 24

Item 3 Quantitative and Qualitative Disclosures About Market Risk 24

Controls and Procedures 24

Item 4 Controls and Procedures 24

OTHER INFORMATION

Part II OTHER INFORMATION

Legal Proceedings 25

Item 1 Legal Proceedings 25

Risk Factors 25

Item 1A Risk Factors 25

Unregistered Sales of Equity Securities and Use of Proceeds 25

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 25

Defaults upon Senior Securities 25

Item 3 Defaults upon Senior Securities 25

Mine Safety Disclosures 25

Item 4 Mine Safety Disclosures 25

Other Information 25

Item 5 Other Information 25

Exhibits 25

Item 6 Exhibits 25 Signatures 25 3 Explanatory Note and Important Cautionary Statement Regarding Forward-Looking Statements As used herein, the terms " MIMEDX, " the " Company, " " we, " " our " and " us " refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc. Certain statements made in this Quarterly Report on Form 10-Q (this " Quarterly Report ") are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the " Securities Act "), and section 21E of the Securities Exchange Act of 1934, as amended. All statements herein relating to events or results that may occur in the future are forward-looking statements, including, without limitation, statements regarding the following: our strategic focus and current business priorities, including broadening of our product portfolio, and our ability to implement these priorities; our expectations regarding costs relating to compliance with regulatory requirements; our expectations regarding capital allocation; our expectations regarding future growth; our expectations regarding the outcome of pending litigation and investigations; our expectations regarding future income tax liability; demographic and market trends; and our ability to compete effectively. Forward-looking statements generally can be identified by words such as "expect," "will," "change," "intend," "seek," "target," "future," "plan," "continue," "potential," "possible," "could," "estimate," "may," "anticipate," "to be" and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company's operations and may cause the Company's actual actions, results, financial condition, performance or achievements to differ materially from any future actions, results, fina

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements MIMEDX GROUP, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) (unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 142,083 $ 104,416 Accounts receivable, net 78,186 55,828 Inventory 26,502 23,807 Prepaid expenses 4,248 5,018 Other current assets 3,076 2,817 Total current assets 254,095 191,886 Property and equipment, net 5,003 5,944 Right of use asset 4,668 5,606 Deferred tax asset, net 21,647 28,306 Goodwill 19,441 19,441 Intangible assets, net 11,147 11,626 Other assets 2,987 1,106 Total assets $ 318,988 $ 263,915 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Current portion of long term debt 1,375 1,000 Accounts payable 11,415 7,409 Accrued compensation 27,650 23,667 Accrued expenses 12,825 9,012 Other current liabilities 4,417 4,507 Total current liabilities 57,682 45,595 Long term debt, net 16,839 17,830 Other liabilities 5,521 7,383 Total liabilities $ 80,042 $ 70,808 Stockholders' equity Common stock; $ 0.001 par value; 250,000,000 shares authorized; 148,075,930 issued and outstanding at September 30, 2025 and 146,932,032 issued and outstanding at December 31, 2024 148 147 Additional paid-in capital 296,670 284,219 Accumulated deficit ( 57,872 ) ( 91,259 ) Total stockholders' equity 238,946 193,107 Total liabilities and stockholders' equity $ 318,988 $ 263,915 See notes to unaudited condensed consolidated financial statements 5 MIMEDX GROUP, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net sales $ 113,725 $ 84,057 $ 300,535 $ 255,972 Cost of sales 18,719 15,322 53,958 43,164 Gross profit 95,006 68,735 246,577 212,808 Operating expenses: Selling, general and administrative 69,001 53,516 193,121 1

View Full Filing

View this 10-Q filing on SEC EDGAR